Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn’s disease Read more
Janssen to adopt Johnson & Johnson brand as the Company celebrates 100 years of operating in the UK Read more
Enlaza Therapeutics Raises $100 Million through Its Series A Financing, Led by the Life Sciences Group of J.P. Morgan Private Capital Read more
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases Read more
Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Read more
Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-In-Class Oral MRGPR Antagonists Read more